Lilly's Mounjaro (tirzepatide) led to more and faster weight loss compared to Novo Nordisk's semaglutide-based drugs

Greater Weight Loss with Mounjaro: Patients using Eli Lilly's Mounjaro (tirzepatide) experienced more significant weight loss compared to those using Novo Nordisk's Ozempic (semaglutide).

High Percentage of Significant Weight Loss: 42.3% of Mounjaro users lost at least 15% of their body weight within one year, in contrast to 19.3% of Ozempic users.

Consistent Weight Loss Over Time: Mounjaro users consistently lost more weight than Ozempic users at 3, 6, and 12-month intervals.

Similar Side Effect Profile: Both groups experienced similar rates of gastrointestinal side effects.

Study Scale and Methodology: The study analyzed health records and pharmacy data of 9,193 patients for each drug, totaling over 18,000 participants. The findings are pending peer review.